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Abstract
Objective: To confirm CXCL10 over production in bone marrow mesenchymal
stem cells (MSCs) and circulating monocytes isolated from multiple sclerosis
patients (MS) and identify predate cell molecular signature; to extend this
analysis after autologous hematopoietic stem cell transplantation (AHSCT) to
test if therapy has modifying effects on MSCs and circulating monocytes. Meth-
ods: MSCs and monocytes were isolated from 19 MS patients who undergone
AHSCT before and seven of them at least 3 years after transplant. CXCL10 pro-
duction was detected after LPS/IFN-c stimulation. TLR4 signaling pathways
were investigated by means of transcription factors phosphorylation/activation
level. RT-PCR of activated transcription factors was performed to quantify their
expression. All experiments were conducted in parallel with 24 matched healthy
donors (HD). Results: CXCL10 expression was significantly increased in both
peripheral circulating monocytes and BM MSCs compared to HD. We showed
that CXCL10 production is determined by an altered signaling pathway down-
stream TLR4, with the involvement of STAT-1, NF-jB, p38, JNK, and CREB.
All upregulated transcription factors are more phosphorylated in MS patient
sample. These features are not modified after AHSCT. Interpretation: We dem-
onstrated that in MS two different cell lineages are characterized by significantly
increased production of CXCL10, due to altered signaling pathways of innate
immune reaction mediated by TLR4, probably associated with disease pheno-
type. This characteristic is not modified by AHSCT, suggesting that when T
and B lymphocytes are reset, other possible components of MS pathology, such
as CXCL10 over production, do not determine therapy outcome.
Introduction
Chronic inflammatory diseases such as multiple sclerosis
(MS) are mediated by the interaction between profes-
sional immune cells and tissue-resident cells. Together
with many factors, the perpetuation of inflammatory
cytokines and chemokines production may maintain
inflammation with consequent impairment of organ tis-
sue. The CXC motif chemokine 10 (CXCL10) is an
inflammatory chemokine that may be produced by differ-
ent cell types such as monocytes, dendritic cells (DC),
endothelial and epithelial cells, and keratinocytes, in
response to IFNc.1 CXCL10 is involved in inflammatory
processes ongoing in RR and SP forms of MS and in a
previous work, we showed that bone marrow (BM)-
derived mesenchymal stem cells (MSCs) isolated from MS
show increased production of CXCL10.2 In this work,
Mazzanti et al. suggested that BM, containing a reticulum
of cells collectively referred to as stromal cells and MSCs
which provide a supportive microenvironment for
growth, differentiation, and proper function of the hae-
matopoietic stem cells (HSCs), may be indicative of a
more wide inflammatory status and may be involved in
disease course and in the outcome of autologous hemato-
poietic stem cell transplantation (AHSCT) treatment.
Although BM has not been widely investigated, several
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authors reported the presence of increased CXCL10 in
serum and cerebrospinal fluid (CSF) of MS, together with
other inflammatory chemokines.3,4 Recently, we observed
in 50 MS CSF, lumbar puncture during acute phase of
disease, that CXCL10 was overexpressed in all analyzed
samples, and this was not true for other chemokines (e.g.,
CXCL13) or cytokines that were only sporadically present
(e.g., IL-17, IFNc or TNFa; C Ballerini, pers comm 2013).
Together, these findings suggest a role of CXCL10 in MS,
such as potent chemoattractant for T lymphocytes, partic-
ularly Th1, NK, and monocytes, cells that participate of
central nervous system (CNS) infiltration determining MS
pathology. Here, we analyzed for the first time CXCL10
production in MS MSCs and peripheral blood (PB)
monocytes before and after AHSCT. We found that in a
sample of 19 MS patients refractory to conventional ther-
apies, augmented CXCL10 production in two different
cell lineages, BM MSCs, and blood circulating monocytes
was a marker of disease and our data show that this was
not due to an altered IFNc production and signaling, but
depends on altered innate immunity TLR4-mediated sig-
naling pathway. AHSCT has the capacity to almost com-
pletely suppress inflammation, can arrest the progression
of disability in 50–70% of severe MS cases, is a powerful
therapy for the malignant forms of MS, and at least with
high intensity conditioning regimens, can induce a reset
of the immunological clock for a period of time of at
least 2 years inducing profound and long-lasting qualita-
tive immunological changes.5,6 CXCL10 is involved in
many inflammatory diseases including MS and it has been
suggested as therapeutic target,7,8 here we investigated if
CXCL10 was a target addressed by AHSCT therapy. In
our study, we found that CXCL10-augmented production
remains unaltered after treatment, indicating that the effi-
cacy of transplantation therapy resides in lymphocytic cell
reset and is not influenced by altered chemokine produc-
tion in BM stromal cells and in circulating monocytes.
Furthermore, our findings add important experience to
the, generally speaking, stem cell therapy in autoimmune
diseases investigating more in detail MS MSCs molecular
signature and MS BM microenvironment.
Methods
Patients
A total of 19 MS patients (10RR/9SP) were enrolled for
AHSCT at the Hematology Unit of Careggi University
Hospital, Florence Italy; characteristics are presented in
Table 1. AHSCT protocol was reported in a previous
work.9 Twenty-four healthy donors, matched for age and
gender, were selected among orthopedic patients and/or
BM donors. Local Ethical Committee approval # Prot.
467/11 was obtained for the study and informed consent
was signed by all patients.
Cells
BM-derived MSCs were isolated and characterized as pre-
viously reported,2 the same for T lymphocytes. Monocytes
were separated from frozen PB cells (106 average cell
number) by mean of positive CD14+ microbeads selection
(Miltenyi Biotec, Bologna, Italy) as reported by Aldinucci
et al.10 mixed lymphocyte reaction (MLR) and anti-CD3-
CD28 stimulation of T cells and proliferative responses as
reported in Mazzanti et al.2
Soluble factors determination
CKs and chemokines production was evaluated in cell
supernatants after 24 h of stimulation (LPS 1 lg/mL;
Sigma; Milano, Italy IFNc 10 ng/mL; eBioscience San Diego
CA USA) and in plasma by ELISA (Quantikine Human
CXCL10 kit; R&D system; Minneapolis MN USA VeriKine
Human IFNb kit; PBL Interferon Source, Piscataway NJ
USA) and Milliplex (Milliplex MAP kits #HCYTOMAG-
60K, #HCVD1-67AK, #HBN1A-51K, #MPXHCYP2-62K-01;
Merck Millipore Darmstadt Germany), following the
manufacturer’s instructions.
Protein phosphorylation
MS MSCs and HD CREB, STAT-1, p38, JNK protein phos-
phorylation have been evaluated by Milliplex (Milliplex
MAP Cell Signaling Buffer and Detection kit #48-602;
Merck Millipore) following the manufacturer’s instructions.
Real-time PCR
MSCs and monocytes mRNA samples extracted and
quantified as reported in Aldinucci et al.10 were investi-
gated by means of real-time PCR for IFNb, NF-jB, IjB,
STAT-1, and CXCL10 using an ABI Prism 7900HT
Sequence Detection System (Applied Biosystem, Foster
City CA USA). All PCR amplifications were performed
on MicroAmp optical 96-well reaction plate with Taqman
Universal Master Mix and using Assay on Demand
(Applied Biosystem). Each assay was carried out in dupli-
cate and included a no-template sample as negative con-
trol. RT negative samples were used to demonstrate that
the signals obtained were RT dependent. Relative expres-
sion of mRNA levels was determined comparing experi-
mental levels to a standard curve generated using serial
dilutions of cDNA obtained from human PBMCs. b-actin
expression levels were used as housekeeping gene for nor-
malization.
ª 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 651
E. Bonechi et al. CXCL10, Stem Cell Therapy, Multiple Sclerosis
Statistics
Results were expressed as mean  standard deviation
(SD). Statistical analysis was performed using Student’s
t-test and Mann–Whitney test where appropriate. Statisti-
cal significance was for P < 0.05.
Results
MS and HD expression of CXCL10 in BM
MSCs and circulating monocytes
MSCs isolated from MS patients produced increased
amount of CXCL10 under LPS stimulation, compared to
controls. Here, we tested MSCs isolated from 19 MS
patients (Table 1) and 24 age-matched controls for
CXCL10 production at three different passages after LPS
stimulation (p2, p4, p6, Fig. 1A). We show that MS
MSCs producing higher quantity of CXCL10 maintain
this peculiarity during cell culture. In addition, we tested
by RT-PCR CXCL10 mRNA production and again MS
MSCs have significant (P < 0.05) increased quantity of
mRNA specific for the investigated chemokine (Fig. 1B).
Among the tested cytokines (IL-1a,b; IL-2-4-6-8-10-
12p40-12p70-17-23, TNFa, OPN, IFNc, GM-CSF, MMP9,
CXCL13, IFNb), we detected production of GM-CSF, IL-
8, IL-6, and OPN; these factors were produced at the
same extent in all samples (Fig. 1C).
Increased CXCL10 production after stimulation of
TLR4 in our cohort of MS patients may be present in PB
cells, that is, monocytes. In Figure 1D, we show that rest-
ing monocytes produced significant (P < 0.03) higher
amount of CXCL10 in MS sample compared with HD
and the same was found upon LPS stimulation
(P < 0.03). Production of CXCL10 is inducible by inter-
ferons, therefore in the same samples we evaluated
CXCL10 production after IFNc stimulation. We showed
no differences in these experimental conditions (Fig. 1E),
suggesting the exclusive involvement of TLR4 signaling
pathway in altered CXCL10 production.
To gain insight into ex vivo cytokine production, we
analyzed BM plasma from patients and controls for the
same soluble factors as we did in cell supernatants: in Fig-
ure 1F, we show that CXCL10 and OPN were present in
a significant different quantity (P = 0.01 and P = 0.04,
respectively) representing a possible marker of MS BM.
Finally, we investigated if AHSCT treatment determines
a difference in CXCL10 production in MSCs, BM plasma,
and circulating monocytes. Seven MS patients underwent
BM biopsy at a median follow-up of 4.5 years (range 3–
7) from AHSCT (clinical data in Fig. 2A); all patients
were monitored after the transplant and no clinical signs
of flair were detected. One patient showed one Gd-
enhancing area 7 years after the procedure. No immuno-
suppressive treatments were administered after the trans-
plant. We showed that MS MSCs and monocytes
preserved higher CXCL10 in vitro production after LPS
stimulation (Fig. 2B and C), as well as CXCL10 amount
is unmodified in BM plasma (Fig. 2D). We may conclude
that monocytes/MSCs production of this fundamental T-
cell homing inflammatory chemokine is a characteristic of
our MS sample and it is not altered by AHSCT. In our
sample, CXCL10 did not correlate with therapy outcome.
MSCs TLR4 signal transduction protein
analysis
To better understand which factors are involved in TLR4
stimulation and consequent CXCL10 production, we ana-
lyzed in MS and HD MSCs phosphorylation state of p38,
CREB, JNK, ERK, and STAT-1. We tested five MS MSCs
and five HD, on basal condition and upon 30 min (p-38,
CREB, JNK, ERK) or 2 h (STAT-1) of LPS stimulation.
MS MSCs expressed higher phosphorylation levels of
p-38, CREB, and JNK after LPS stimulation compared
with HD MSCs (P < 0.05) (Fig. 3A). p38, JNK, CREB,
and STAT-1 could be the signaling factors responsible for
CXCL10 production in MS MSCs under LPS stimulation.
On the other hand, MS and HD MSCs showed no change
in the phosphorylation level of ERK (not shown), suggest-
ing that ERK was not implicated in the signaling cascade
responsible for CXCL10 production. Analysis of phos-
phorylation in samples post-AHSCT showed the same
level of factor activation (Fig. 3B).
Table 1. Patient characteristics.
Patients no. Gender (F:M)
Age at AHSCT
median (range)
Disease duration
years median (range)
EDSS median
(range)
Last therapy before AHSCT no. of patients/total
no. of patients)
Cy Mtx Nb Fg IFNp PE
Eleven RR-MS 8:3 28 (17–43) 10 (2–20) 6.0 (2–6.5) 5/11 2/11 2/11 1/11 0/11 1/11
Eight SP-MS 8:0 30 (19–53) 20 (11–33) 6.5 (4–6.5) 6/8 1/8 0/8 0/8 1/8 0/8
Cy, cyclophosphamide; Mtx, mitoxantrone; Nb, natalizumab; Fg, fingolimod; IFNb, interferon b; PE, plasma exchange.
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MSC/monocyte expression of TLR4 signaling
factors
Transductional analyses indicated that TLR4 signaling
cascade is altered in terms of activation. Level of mRNA
was quantified for p38, STAT-1, JNK, CREB, NF-jB, and
IkB on basal conditions and LPS stimulation (4 h) by
real-time PCR in MS and HD MSCs and monocytes. In
patient cells, STAT-1, NF-jB, and IjB expression levels
were significantly upregulated (P < 0.02) after LPS stimu-
A B C
D E F
Figure 1. MSCs/monocytes CXCL10 production before AHSCT. (A) MSCs from 19 multiple sclerosis (MS) patients (gray circles) and 24 healthy
donors (HD, black circles) were analyzed for CXCL10 production upon LPS stimulation at three in vitro passages, P2, P4, and P6. MSCs were
plated in 24-well plates at the density of 1 9 105 cells/mL, incubated for 24 h with LPS 1 lg/mL. CXCL10 was measured on cell supernatants by
ELISA. Each point in the graph corresponds to an independent MSC sample; horizontal bars represent CXCL10 mean value (pg/mL). Here, we
show that MS MSCs produce higher level of CXCL10 with respect to controls at each tested passage. CXCL10 mean production is significantly
higher in MS MSCs than HD MSCs at each passage (**P < 0.002 at P2, *P < 0.05 at P4, ***P < 0.001 at P6, nonparametric two-tailed t-test). (B)
CXCL10 production was tested by real-time PCR on eight MS MSCs (gray Whiskers box plot) and eight HD (black Whiskers box plot) in basal
condition () and upon stimulation with LPS for 4 h (+LPS). mRNA expression level is reported as ratio to b-actin. CXCL10 mean expression in MS
MSCs is significantly higher than HD samples under stimulated condition (*P < 0,05, nonparametric two-tailed t-test). (C) All MS and HD MSCs
included in the study were tested after LPS stimulation, for the production of the cytokines IL-1a-1b-2-4-6-10-12p40-12p70-17-23, TNFa, OPN,
IFNc, GM-CSF, MMP9, and CXCL13 by Milliplex, and for IL-8, IFNb production by ELISA. Here, we show that MSCs produce GM-CSF, IL-8, IL-6,
and OPN, without any difference between MS and HD samples (mean values, expressed as pg/mL, SEM are reported). (D) CXCL10 production
was investigated in six MS and six HD samples of peripheral CD14+ monocytes under basal condition () and upon LPS stimulation (+LPS) by
Milliplex. Monocytes were plated in 24-well plates at the density of 1 9 106 cells/mL and then incubated for 24 h with or without LPS 1 lg/mL.
Here, we show that MS monocytes produce higher level of CXCL10 than controls before and after LPS stimulation (P < 0,03, Mann–Whitney
test). (E) In the same MSCs and monocytes samples analyzed as above, we evaluated CXCL10 production after IFNc stimulation (10 ng/mL for
24 h) by ELISA. All MSCs and monocytes produce CXCL10 in response to IFNc, without any difference between MS and HD. (F) BM plasma of
seven MS patients and six HD was tested ex vivo for cytokines. The presence of IL-1a,b; IL-2-4-6-IL10-12p40-12p70-17-23, TNFa, OPN, IFNc, GM-
CSF, MMP9, and CXCL13 was evaluated by Milliplex; IL-8 and IFNb were tested by ELISA. Among the tested cytokines, we found that BM plasma
contains CXCL10, CXCL13, MMP-9, OPN, and IFNb; MS samples contain significantly higher amounts of CXCL10 (**P = 0.01, Mann–Whitney
test) and OPN (*P = 0.04, Mann–Whitney test) than HD ones. HD, healthy donors; MS, multiple sclerosis; MSCs, mesenchymal stem cells.
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lation (Fig. 4A and B), whereas p38, JNK, and CREB not
(not showed). Furthermore, we found a significant corre-
lation (Fig. 4C and D) among STAT-1, NF-jB, and
CXCL10 production (P < 0.01). In Figure 4E, we showed
that expression levels of analyzed factors remain unaltered
post-AHSCT in MSCs and monocytes.
Discussion
CXCL10, a chemochine with inflammatory and homing
role, is increased in serum and CSF of MS patients indicat-
ing that MS pathophysiology is, in part, supported by
CXCL10 production by different cell types.11 Here, we
found that BM-derived MSCs and PB monocytes isolated
from RR/SP MS produced significant increased amount of
CXCL10 when stimulated through TLR4, independently
on the RR/SP clinical course (data not shown). Of note,
we measured an in vitro response in cultured cells that is
in agreement with ex vivo results in BM plasma and
strongly suggests that this might be a representation of in
vivo situation. Indeed, innate immune response has been
involved in MS pathogenic mechanisms in periphery and
in CNS and it is believed that pathogen-associate molecu-
lar patterns (PAMPs) receptors have a role in determining
MS inflammatory pattern and possibly influence clinical
course as it happens in MS animal model.12,13 The specific
A
B C D
Figure 2. CXCL10 production after AHSCT. (A) Follow-up and clinical characteristics of seven of 19 MS patients after AHSCT. Left panel: at long-
term follow-up, with a median of 4.5 years (range 3–7), patients had stable EDSS (29%), improved EDSS (57%) and only 1 (14%) progressed.
Middle panel: whiskers box plots show EDSS modification according to the time from AHSCT. Right panel: no MRI activity was evidenced after
AHSCT except for one patient who showed a new enhanced lesion 7 years after AHSCT, in absence of clinical relapse or clinical progression. (B)
MSCs CXCL10 production after AHSCT. CXCL10 production was measured by ELISA in supernatants of MSCs isolated from seven patients before
(pre) and after AHSCT (post) at three different passages, P2, P4, and P6, after LPS stimulation (24 h). MSCs POST AHSCT produce CXCL10 as
MSCs PRE AHSCT. C) CXCL10 production in peripheral monocytes isolated from four MS patients before and after AHSCT. CXCL10 production
was tested (Milliplex) in basal condition () and upon stimulation with LPS for 24 h (+LPS). As shown by column bar graph (pg/mL mean  SEM),
monocytes POST AHSCT produce CXCL10 at similar extent with respect to monocytes PRE AHSCT. MS, multiple sclerosis; MSCs, mesenchymal
stem cells; AHSCT, autologous hematopoietic stem cell transplantation.
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involvement of TLR4 in our altered CXCL10 production is
in agreement with our data on phosphorylation of mole-
cules associated with TLR4 signaling pathway, augmented
after LPS stimulation when compared to HD. Different
from data reported in a previous work14 where T lympho-
cytes and monocytes were investigated, the increase in
STAT-1 phosphorylation in MS MSCs is independent on
disease activity (i.e., before and after transplantation) and
we did not find any correlation with transcription factors
expression and production of IFNc, IL-10, and IL-6. We
think that our data identify more a cell signature corre-
lated with MS than a transitory marker of disease activity.
Extending the observation to signal transduction factors
downstream TLR4 pathway expression in monocytes/
MSCs of the same sample, we showed that mRNA level for
NF-jB, STAT-1, and IkB is increased in terms of relative
expression and correlates with CXCL10 production. This
suggests that in our MS sample TLR4, that may be elicited
by PAMPs of bacterial origin as well as by self-molecules
derived from stressed cells (i.e., heat-shock proteins,
HSPs15 or extracellular matrix components16), is more
activated in two different, for origin and function, cell lin-
eages. Indeed, TLR4 activation may contribute to disease
by different routes. First, increased activation of TLR4 may
be responsible for an increased systemic inflammation
with consequent effects on axon injury and disease pro-
gression, following the hypothesis of the occurrence of an
immune-mediated neurodegenerative process in MS.17
Second, as both T and B cells do express TLRs, increased
responsiveness of TLR4 may interact as costimulatory fac-
tor, influencing T-cell regulatory response.18 Third, TLR4
is present in CNS-resident cells such as astrocytes and mi-
croglia and mediates immune response during inflamma-
tion; in particular, TLR4 ligands are known to be present
A  
B 
Figure 3. Signal transduction protein analysis. (A) The activation state of the signaling proteins p-38, CREB, JNK, and STAT-1 was investigated by
Milliplex in five MS MSCs and five HD ones, on basal condition () and upon LPS stimulation (30 min for p-38, CREB and JNK, 2 h for STAT-1).
For each analysis, 10 lg of total extracted proteins was used. The graphs show the ratio between phosphorylated protein and total protein levels
(ph protein/tot protein), expressed as mean value  SD. MS MSCs have higher level of ph p-38, ph CREB, ph JNK, and ph-STAT-1 than HD MSCs
(*P < 0.05, Mann–Whitney test). (B) The activation state of p-38, CREB, JNK, and STAT-1 was also investigated in MS MSCs isolated after AHSCT
(MS MSCs POST AHSCT) from the same patients analyzed in A) The phosphorylation level upon LPS stimulation is expressed as fold increase with
respect to basal condition (ratio between ph protein/tot protein value in stimulated condition and ph protein/tot protein value in basal condition)
and compared with pre-AHSCT (MS MSCs PRE AHSCT) and HD values (HD MSCs). Here, we show that after AHSCT MS MSCs preserve the same
phosphorylation levels of p-38, CREB, JNK, and STAT-1 observed before AHSCT, and these are significantly increased compared with HD samples
(*P < 0.04; **P < 0.001). HD, healthy donors; MSCs, mesenchymal stem cells; AHSCT, autologous hematopoietic stem cell transplantation; MS,
multiple sclerosis; MSCs, mesenchymal stem cells.
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in MS lesions.19 Recently, increased expression of TLR3,
and to a lesser extent TLR4, has been described in MS-cir-
culating cells and it has been reported to be responsible
for increased innate immune response activation along
with augmented production of CXCL10.20 These authors
hypothesize that differential TLRs expression may modu-
late inflammation and may be associated with MS clinical
courses. Increased expression of TLR4 and TLR2 and rela-
tive signaling pathways has been described in na€ıve CD4+
T lymphocytes isolated from secondary progressive MS
(SP MS).21 These authors conclude that SP MS CD4+ T
lymphocytes are biologically different from HD in terms
of cell activation and this functional disregulation is asso-
ciated with a subgroup of SP MS patients characterized by
a strong response to anti-inflammatory therapies. Here, we
followed the evidence that altered TLR4 activation, and
not altered expression (data not shown and reference [2])
in BM MSCs and circulating monocytes, and probably in
CNS-resident cells, is a characteristic of a cohort of MS
patients, all refractory to conventional therapies but good
responders to AHSCT. The consequent augmented
CXCL10 production could be one of the factors that deter-
mines, establishing an inflammatory loop, the observed
disease phenotype as it has been previously reported in
A
B
C
D
E
Figure 4. Signaling protein expression profile. (A and B) STAT-1, NF-jB, and IjB expression was evaluated by real-time PCR in MSCs (A) and in
peripheral monocytes (B) isolated from six MS patients (gray columns) and six HD (black columns). mRNA expression levels of STAT-1, NF-jB, and
IjB were determined in basal condition () and upon LPS stimulation for 4 h (+LPS). mRNA expression is reported as ratio to b-actin (relative
expression). Upon LPS stimulation, both MS MSCs (A) and MS monocytes (B) express higher levels of STAT-1, NF-jB, and IjB than HD ones
(*P < 0.05, **P < 0.02, Mann–Whitney test). (C and D) Correlation between CXCL10 production (pg/mL) and STAT-1/NF-jB relative expression in
MS MSCs (C) and MS monocytes (D) upon LPS stimulation. Each point in graphs represents an independent sample. Linear regression between
CXCL10 (pg/mL) and STAT-1/NF-jB relative expression is statistically significant both in MSCs and in monocytes (P value and r2 value are reported
in each graph). (E) STAT-1, NF-jB, and IjB expression evaluated by real-time PCR in MS MSCs and peripheral monocytes after AHSCT and
compared as fold increase with pre-AHSCT and HD values. Cells were isolated from the same MS patients before and after AHSCT. mRNA
expression level of STAT-1, NF-jB and IjB was determined in basal condition () and upon LPS stimulation for 4 h (+LPS). Expression was
evaluated as ratio to b-actin. Here, we show that transcription factors expression is still significantly increased in MS compared with HD
(*P < 0.05) independently on AHSCT treatment. MSCs, mesenchymal stem cells; AHSCT, autologous hematopoietic stem cell transplantation.
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two not LPS-induced models of autoimmune arthritis.22
In this scenario, TLR4 should have been a possible AHSCT
target in MS therapy.23 On the contrary, our data show
that autologous transplantation does not modify the
altered TLR4 signaling pathway and consequent CXCL10
hyperproduction, detected in BM and periphery cells. On
the other hand, CXCL10-producing MSCs and increased
CXCL10 in plasma BM, together with OPN, were recently
shown not to be associated with disease activity, probably
contributing to dysregulation of T-cell survival,24,25
thereby influencing the outcome of AHSCT.26 Against this
hypothesis, our data show that the BM-altered microenvi-
ronment does not affect the therapy’s efficacy. Taken
together, the present results support the idea that other
mechanisms are involved in AHSCT efficacy as reconstitu-
tion of lymphocyte cell repertoire.27 We suggest that when
the principle MS effector arm (adaptive immunity) is
affected innate immunity mechanisms lose their influence
on the disease course and on the outcome of the therapy.
Finally, in our study, we confirm the partially different
nature of MS MSCs compared to HD, not only for the
production of CXCL10 after LPS stimulation but also for
down-modulation of autologous T cells during prolifera-
tive response, that results reduced (Aldinucci pers comm
2014). In a previous work, we demonstrated that MS
MSCs are able to down-modulate T-cell proliferative
response during MLR and shift DCs toward less immuno-
genic action;2 the fact that they fail to reduce proliferation
of autologous T cells despite they maintain the strong
immunomodulatory effects on DCs is in agreement with
other author observations.28 Ultimately, it has been
hypothesize that CXCL10 over production might contrast
possible MSCs cancer-inducing effects. Indeed, together
with monocytes, neutrophils, and lymphocyte, recruit-
ment activity CXCL10 acts as antiangiogenic chemokine
and it has been shown that adipose-derived MSCs trans-
fected with CXCL10 gene downregulate MMP2 and Bcl2,
and this correlates with a strong antitumor activity.29
In conclusion, our study, although performed with a
small sample, individuates a molecular signature corre-
lated with MS patients who were all good responders to
AHSCT, and adds new knowledge to AHSCT mechanisms
and MS MSCs nature. In the future, it should be impor-
tant to further investigate MS patients for TLR4 pathway
in T and B lymphocytes and to attempt identification of
possible epigenetic factors responsible for the reported
increase in innate immune activation.
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